Sabratek purchasing controls for pre-filled syringes inadequate, FDA says in Dec. 12 warning letter.
This article was originally published in The Gray Sheet
Executive SummarySABRATEK PURCHASING CONTROLS FOR IV FLUSH SYRINGES INADEQUATE, FDA SAYS in a Dec. 12 warning letter to the company. The agency cites Sabratek's Woburn, Massachusetts-based Rocap facility for failing to test incoming products such as syringe, heparin injection, and saline injection components. In addition, "suppliers of incoming product are neither audited nor under any written agreement." The warning letter follows an inspection conducted between Aug. 28 and Sept. 29.
You may also be interested in...
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.